Vaccine Access, Uptake, Effectiveness and Safety in First Nations Communities
The objectives of this study is to understand the immune response and safety of the COVID-19 vaccine in First Nations people who have been disproportionately affected by the pandemic, and have worse outcomes from COVID-19 infection compared to other groups.
The study also aims to understand why some people are not as confident in the COVID-19 vaccine as others, and to document the overall impact of COVID-19 in these communities. The study will also provide insight into how a pandemic of this scale can be prevented in these communities and other vulnerable populations.
Overview
- Acronym
- COVID CommUNITY First Nations
- Website
- COVID CommUNITY First Nations
- Investigators
-
- Contacts
-
General Design
- Study design
- Cohort
- Start - End Year
- 2021 - 2022
- General Information on Follow Up (profile, frequency)
-
Participants were followed up for 6 to 12 months.
- Recruitment Target
-
- Individuals
- Number of Participants
- 3,000
- Number of Participants with Biological Samples
- 3,000
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
|
Timeline
Population
COVIDCommUNITY-FN population
The population is composed of individuals from First Nations communities in Quebec, Ontario and Saskatchewan who are at least18 years old.
Selection Criteria
- Minimum age
-
18
- Countries
-
- Canada
- Canadian Provinces
-
- Ontario
- Quebec
- Saskatchewan
- Ethnic Origin
-
- Inclusion criteria: First nations
- Other Criteria
- Exclusion criteria: If study assessment cannot be completed such as dried blood sample (DBS)
Sources of Recruitment
- Specific Population
-
- Other specific population : Participants identified on-site at the Vaccine/Assessment Centres
- Participants from Existing Studies
-
- COVID CommUNITY prospective cohort studies
- Supplementary Information
-
Participants were recruited from First Nations communities: * From vaccination or assessment centres and; * By re-contacting participants (18+) from our on-going prospective cohort studies via telephone/email.
Sample Size
- Number of Participants
- 3,000
- Number of Participants with Biological Samples
- 3,000
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | COVIDCommUNITY-FN - Baseline |
|
|
2021 (April) | 2021 (December) |
| 1 | COVIDCommUNITY-FN - 6 months follow-up |
|
|
2021 (November) | 2022 (June) |
| 2 | COVIDCommUNITY-FN - 12 months follow-up |
|
|
2022 (April) | 2022 (December) |
Participating Studies
| Acronym | Name | Study design | Countries |
|---|
Harmonization Initiatives Included
| Acronym | Name |
|---|
Datasets
| Name | Data Collection Events | Variables |
|---|
Areas of Information Collected
- Socio-demographic and economic characteristics
- Death
- Lifestyle and behaviours
- Physical measures and assessments
- Birth, pregnancy and reproductive health history
- Laboratory measures
- Perception of health, quality of life, development and functional limitations
- Cognition, personality and psychological measures and assessments
- Diseases
- Life events, life plans, beliefs and values
- Symptoms and signs
- Preschool, school and work life
- Medication and supplements
- Social environment and relationships
- Non-pharmacological interventions
- Physical environment
- Health and community care services utilization
- Administrative information
Variables Content Summary
Areas of Information Collected
No Areas of Information Collected
No Scales Collected
Areas of Information Collected per per Population and Data Collection Event
No Areas of Information Collected
No Scales Collected
Networks
| Acronym | Name | Harmonization Initiatives | Individual Studies |
|---|
Last Update: 2024-02-27T12:06:05.802